Lacosamide, the new anticonvulsant, effectively reduces harmaline-induced tremors in rats

European Journal of Pharmacology

Volumn 589, Issue 1-3, 2008, Pages 114-116

  Stöhr, Thomas ^a   Lekieffre, Delphine ^b   Freitag, Joachim ^a  

^a Schwarz Pharma AG   (Germany)

^b MDS Pharma Services   (Switzerland)

Author keywords

Antitremorgenic drug; Essential tremor; Harmaline; Lacosamide

Indexed keywords

ANTICONVULSIVE AGENT; HARKOSERIDE; HARMALINE; PRIMIDONE; PROPRANOLOL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFICACY; ESSENTIAL TREMOR; IN VIVO STUDY; LATENT PERIOD; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; TREMOR;

ACETAMIDES; ANIMALS; ANTICONVULSANTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ESSENTIAL TREMOR; HARMALINE; MALE; PRIMIDONE; PROPRANOLOL; RATS; RATS, SPRAGUE-DAWLEY; REACTION TIME;

EID: 47749135207     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.06.038     Document Type: Article

References (15)

1. Arshaduddin M., Al Kadasah S., Biary N., Al Deeb S., Al Moutaery K., and Tariq M. Citalopram, a selective serotonin reuptake inhibitor augments harmaline-induced tremor in rats. Behav. Brain Res. 153 (2004) 15-20
2. Beyreuther B.K., Freitag J., Heers C., Krebsfänger N., Scharfenecker U., and Stöhr T. Lacosamide: a review of preclinical properties. CNS Drug Rev. 13 (2007) 21-42
3. Brandt C., Heile A., Potschka H., Stöhr T., and Löscher W. Effects of the novel antiepileptic drug lacosamide on the development of amygdale kindling in rats. Epilepsia 47 (2006) 1803-1809
4. Chen J.J., and Swope D.M. Essential tremor: diagnosis and treatment. Pharmacotherapy 23 (2003) 1105-1122
5. Doty P., Rudd G.D., Stöhr T., and Thomas D. Lacosamide. Neurotherapeutics 4 (2007) 145-148
6. Iwata S., Nomoto M., and Fukuda T. Effects of beta-adrenergic blockers on drug-induced tremors. Pharmacol. Biochem. Behav. 44 (1993) 611-613
7. Koller W.C., and Vetere-Overfield B. Acute and chronic effects of propranolol and primidone in essential tremor. Neurology 39 (1989) 1587-1588
8. Louis E.D. Essential tremor. Lancet Neurol. 4 (2005) 100-110
9. Louis E.D., Zheng W., Applegate L., Shi L., and Factor-Litvak P. Blood harmane concentrations and dietary protein consumption in essential tremor. Neurology 65 (2005) 391-396
10. Martin F.C., Thu Le A., and Handforth A. Harmaline-induced tremor as a potential preclinical screening method for essential tremor medications. Mov. Disord. 20 (2005) 298-305
11. Pahwa R., and Lyons K.E. Essential tremor: differential diagnosis and current therapy. Am. J. Med. 115 (2003) 134-142
12. Pennes H.H., and Hoch P.H. Psychotomimetics, clinical and theoretical considerations: harmine, WIN-2299 and Nalline. Am. J. Psychiatry 113 (1957) 887-892
13. Stöhr T., Kupferberg H.J., Stables J.P., Choi D., Harris R.H., Kohn H., Walton N., and White H.S. Lacosamide, a novel anti-convulsant drug, shows efficacy with a wide safety margin in rodent models for epilepsy. Epilepsy Res. 74 (2007) 147-154
14. Wilms H., Sievers J., and Deuschl G. Animal models of tremor. Mov. Disord. 14 (1999) 557-571
15. Zesiewicz T.A., Elble R., Louis E.D., Hauser R.A., Sullivan K.L., Dewey R.B., Ondo W.G., Gronseth G.S., and Weiner W.J. Practice parameter: therapies for essential tremor. Neurology 64 (2005) 2008-2020